A Randomized, Placebo-Controlled, Multi-Site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation (The ADV HALT Trial) Amendment 3
|Effective start/end date||10/31/11 → 12/31/13|
- Chimerix, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.